In development, there is considerable debate and uncertainty about two related concepts: whether the poor can pay for important health products and whether paying customers value these goods more than recipients of hand outs. The first is a question of whether or not people have the resources and are even willing to pay for basic health products like anti-malarial bednets or water purification filters or tablets.Â
As an investor in a long-lasting bednet manufacturer in Tanzania, we know that people are not willing to pay the full cost of the bednets, but they are willing to pay for subsidized nets. Just how big a subsidy is required is a question that we are exploring right now with Professor Pascaline Dupas of Dartmouth. With the support of Sumitomo, the Exxon Mobil Foundation, and an anonymous donor, we are conducting a randomized trial to find the price at which people will buy them. We are also reviewing the literature to see if there is a definitive opinion on whether people who buy nets vs. those who receive them for free are more likely to invest the time and energy into figuring out how to use them properly, and ultimately receive the health benefit of reduced exposure to mosquitoes with proper use of the bednet.Â
This study from the Poverty Action Lab takes up the same set of questions for water purification tablets in Zambia. The findings are fascinating, and show that in this experiment, people who paid for the Clorin were more likely to use it than those who were given it. The next step is to study whether a market for public health products can be an important complement to other essential government and NGO strategies to reach those in need with access to clean water or preventative health products and medicines.

One of my toughest days working in this field was recently, when we went to the Mukuru slums to visit one of the sites operated by a business we are considering funding. I’ve been in some of the poorest places in the world - in places far afield as Peru, Pakistan, Honduras, India, South Africa, Brazil and beyond. But I don’t ever recall being as disheartened as during my visit here.
Acumen Fund has just put out its
In January, the